{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:11Z","timestamp":1791908291055,"version":"4.3.4"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Neuropharm"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Cladribine is a selective and oral immunological reconstitution treatment, approved in Europe for very active multiple sclerosis (MS) with relapses. Aims were to assess the safety and effectiveness of cladribine in real-world setting, during treatment follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a multicentric, longitudinal, observational study with retrospective and prospective data collection of clinical, laboratory, and imaging data. This interim analysis reports data from July 1, 2018 (study onset), to March 31, 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 182 patients were enrolled: 68.7% were female; mean age at onset was 30.1 \u00b1 10.0 years, and mean age at first cycle of cladribine treatment was 41.1 \u00b1 12.1; 88.5% were diagnosed with relapse-remitting MS and 11.5% with secondary progressive MS. Mean disease duration at cladribine start was 8.9 \u00b1 7.7 years. Most patients (86.1%) were not naive, and median number of previous disease-modifying therapies was 2 (interquartile range, 1\u20133). At 12 months, we observed no significant Expanded Disability Status Scale score worsening (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.843, Mann-Whitney <jats:italic toggle=\"yes\">U<\/jats:italic> test) and a significantly lower annualized relapse rate (0.9 at baseline to 0.2; 78% reduction). Cladribine treatment discontinuation was registered in 8% of patients, mainly (69.2%) due to disease activity persistence. Most frequent adverse reactions were lymphocytopenia (55%), infections (25.2%), and fatigue (10.7%). Serious adverse effects were reported in 3.3%. No patient has discontinued cladribine treatment because of adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our study confirms the clinical efficacy and the safety profile of cladribine for treating MS patients with a long-term active disease in the real-world setting. Our data contribute to the body of knowledge of the clinical management of MS patients and the improvement of related clinical outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/wnf.0000000000000552","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T18:02:05Z","timestamp":1681149725000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Safety and Effectiveness of Cladribine in Multiple Sclerosis: Real-World Clinical Experience From 5 Tertiary Hospitals in Portugal"],"prefix":"10.1097","volume":"46","author":[{"given":"M\u00f3nica","family":"Santos","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Neurologia, Departamento de Neuroci\u00eancias e Sa\u00fade Mental, Hospital Santa Maria\/CHULN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Sequeira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de Lisboa Central, E.P.E., Lisboa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guerreiro","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar de Set\u00fabal E.P.E., Set\u00fabal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Santos","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal, Universidade do Porto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Brum","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de Lisboa Central, E.P.E., Lisboa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Ladeira","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de Lisboa Central, E.P.E., Lisboa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Leit\u00e3o","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal, Universidade do Porto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Salgado","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal, Universidade do Porto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Capela","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Centro Hospitalar Universit\u00e1rio de Lisboa Central, E.P.E., Lisboa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"de S\u00e1","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Departamento de Neuroci\u00eancias e Sa\u00fade Mental, Hospital Santa Maria\/CHULN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458517708667","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: results for Portugal","volume":"23","year":"2017","journal-title":"Mult Scler"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1756286420935019","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1212\/WNL.96.15_supplement.2942","article-title":"Real-world experience with cladribine tablets in the MSBase Registry (2942)","volume":"96","year":"2021","journal-title":"Neurology"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase Registry substudy","volume":"27","year":"2021","journal-title":"Mult Scler"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","year":"2022","journal-title":"Mult Scler"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"102945","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-centre, analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","year":"2021","journal-title":"Mult Scler Relat Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:04:42Z","timestamp":1750525482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0000000000000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0000000000000552","relation":{},"ISSN":["1537-162X","0362-5664"],"issn-type":[{"value":"1537-162X","type":"electronic"},{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}